MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · IEX Real-Time Price · USD
0.910
-0.007 (-0.75%)
Apr 18, 2024, 1:54 PM EDT - Market open
MiNK Therapeutics Stock Forecast
INKT's stock price has decreased by -58.58% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for MiNK Therapeutics stock has a target of 9.00, which predicts an increase of 889.01% from the current stock price of 0.91.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for INKT is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +889.01% | Mar 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +998.90% | Aug 10, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +998.90% | May 12, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +669.23% | Apr 19, 2023 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | +229.67% | Mar 22, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.57
from -0.65
EPS Next Year
-0.61
from -0.57
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 102.4M | 259.7M |
| Avg | n/a | n/a | n/a | 39.5M | 188.5M |
| Low | n/a | n/a | n/a | n/a | 119.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 557.3% |
| Avg | - | - | - | - | 377.1% |
| Low | - | - | - | - | 203.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.54 | -0.57 | -0.53 | 0.08 | 1.43 |
| Avg | -0.57 | -0.61 | -0.62 | -0.53 | 0.62 |
| Low | -0.65 | -0.63 | -0.71 | -0.89 | -0.14 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.